Last year, Ultragenyx Pharmaceutical Inc generated 304.00M USD for its biggest-performing segment, Crysvita royalty revenue. The North America made the largest contribution, accounting for 377.00M USD last year. For the latest quarter, Ultragenyx Pharmaceutical Inc reported the revenue of 102.00M USD for the period ending 2026-06-30, which came from the top-performing segment, Crysvita royalty revenue. North America contributed the highest revenue, at 121.00M USD.